India orders new drug-making standards after overseas deaths

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-01-06 11:01 GMT   |   Update On 2024-03-27 07:04 GMT
Advertisement

New Delhi: Indian pharmaceutical companies must meet new manufacturing standards this year, according to a government notification released on Saturday, although small companies have asked for a delay, citing their debt load.

Jolted by a string of overseas deaths linked to Indian-made drugs since 2022, Prime Minister Narendra Modi's government has stepped up scrutiny of pharmaceutical factories to clean up the image of the $50 billion industry.

Advertisement

"The manufacturer must assume responsibility for the quality of the pharmaceutical products to ensure that they are fit for their intended use, comply with the requirements of the licence and do not place patients at risk due to inadequate safety, quality or efficacy," said the notification, dated Dec. 28.

Companies must market a finished product only after getting "satisfactory results" on tests of the ingredients and retain a sufficient quantity of the samples of intermediate and final products to allow repeated testing or verification of a batch, it says.

The health ministry said in August that inspections of 162 drug factories since December 2022 found an "absence of testing of incoming raw materials". It said fewer than a quarter of India's 8,500 small drug factories met international drug manufacturing standards set by the World Health Organization (WHO).

The notification said those concerns must be addressed by large drugmakers within six months and small manufacturers in 12 months. Small companies had asked for the deadline to be extended, warning that investments required to meet the standards would shut down nearly half of them because they are already heavily indebted.

The WHO and other health authorities have linked Indian cough syrups to the deaths of at least 141 children in Gambia, Uzbekistan and Cameroon.

Original news source: https://www.reuters.com/business/healthcare-pharmaceuticals/india-orders-new-drug-making-standards-after-overseas-deaths-2024-01-06/ 

Read also: Maiden Pharma denies tampering with tests in probe of cough syrup deaths

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News